Considering this study, we propose individuals with LS should have surveillance by EGD (every 1–3 y) from the age of 30–35 y and testing of HP injection, and then, individuals with LS‐associated initial GC should have surveillance with EGD (every year) after the initial GC. Here, HP is linked to gastric cancer.